In a phase 1 trial of patients with advanced systemic mastocytosis, avapritinib, a selective KIT inhibitor, was generally well tolerated, elicited durable clinical responses and led to reductions in mast cell disease burden. The gene discussed is KIT; the disease is maculopapular cutaneous mastocytosis.